From the lab to clinic: the patient-centered and tight trinity of investments, R&D and patent control

The presentation aims at highlighting several moments in time important for a patent strategy, during the long period from drug discovery up to market introduction, pricing & reimbursement and ultimately access for patients. Groundbreaking inventions relating to the applicability of a known or new molecule (antibody, small molecule, peptide, oligonucleotide, etc.) for treating or preventing a disease often stem from academic research. 

Securing early though decisive measures to gain control over the further development program therefore lie in the hands of universities and academic hospitals, and their tech transfer / valorization officers. If budget allows, building a sound patenting strategy cannot start early enough. If there is a slightest chance that a relevant patient population might benefit enormously from such future new therapy becoming available to them, first patenting rather then (first) publishing is key. The more since such IP strategy paves the way towards investment-ready opportunities, once relative high capital demand is apparent for conducting the necessary clinical trials. Step-by-step, Barend will guide the audience through the important milestones and events that trigger relevant aspects of designing and executing the optimal IP strategy.